Review anchor
Indoleamine 2,3-dioxygenase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Indoleamine 2,3-dioxygenase 1
CHEMBL4685
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Indoleamine 2,3-dioxygenase 1 as ChEMBL target CHEMBL4685, mapped to UniProt P14902. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4685
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P14902
Indoleamine 2,3-dioxygenase 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Indoleamine 2,3-dioxygenase 1 matters
Indoleamine 2,3-dioxygenase 1 is reviewed as Indoleamine 2,3-dioxygenase 1 (UniProt P14902); Indoleamine 2,3-dioxygenase 1 shows late clinical disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 10 approved drugs, 5262 compounds, and 799 assays, with lead potency reaching pChEMBL 10.7.
Protein context
Indoleamine 2,3-dioxygenase 1
Indoleamine 2,3-dioxygenase 1 Sequence length is 403 aa.
Review this target as Indoleamine 2,3-dioxygenase 1, mapped to UniProt P14902. Sequence length is 403 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P14902
Protein
Disease context
cancer
Indoleamine 2,3-dioxygenase 1 shows late clinical disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include EPACADOSTAT, LINRODOSTAT.
Start review with cancer because it currently carries late clinical support. Linked drugs include EPACADOSTAT, LINRODOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Late clinical
2 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 10 approved drugs, 5262 compounds, and 799 assays for this target. The dominant activity type is IC50. CHEMBL432537 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL432537 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
10 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Indoleamine 2,3-dioxygenase 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P14902, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why cancer is currently treated as late clinical support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
5262
Total Compounds
799
Total Assays
10
Approved Drugs
IC50: 6923.0, KI: 224.0, EC50: 360.0, KD: 73.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL432537
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL5207194
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL4645108
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL4863767
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL5192384
|
10.0 | Ki | — |
Source Header